Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab.

Subjects have rolled over from parent study, i.e., CLR\_16\_23, into the long-term extension study CLR\_18\_07. The study has been open label post 1 year completion.